from GLITR
needs edits to make it into the main article
Ann Arbor-based Compendia Bioscience Thursday announced the release of Oncomine Concepts Edition version 4.0, the latest incarnation of the company's flagship product. Since its inception at the University of Michigan, Oncomine has been rapidly adopted by drug discovery and development organizations looking to improve results of cancer drug development efforts. This new version of Oncomine features an improved user interface and new export function that allows results sharing. Cancer researchers and drug developers have made Oncomine the industry standard, with 15 of the top 20 cancer research companies using this product for interactive access and in-depth analysis of curated cancer genomics data. More.
http://www.wwj.com/pages/4091644.php?
Compendia Bioscience is dedicated to harnessing the global collection of high throughput molecular data to provide researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical outcomes.
More at http://www.compendiabio.com.
Oncomine combines a rapidly growing compendium of more than 30,000 expertly curated cancer genomic profiles with a sophisticated analysis engine and a powerful web application for data mining and visualization. Oncomine facilitates target discovery and validation and supports the prioritization of tumor populations for drug development.